These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 6535137)

  • 1. [A case of systemic sclerosis in childhood complicated by severe digital ulcers].
    Falcini F; Volpi M; Pierattelli M; Taccetti G; Pratesi G; Matucci Cerinich M
    Pediatr Med Chir; 1984; 6(5):703-7. PubMed ID: 6535137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
    Gore J; Silver R
    Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
    [No Abstract]   [Full Text] [Related]  

  • 4. [Sclerodermic acrosyndromes].
    Carpentier PH
    Rev Prat; 2002 Nov; 52(17):1891-5. PubMed ID: 12532865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic sclerosis: bilateral improvement of Raynaud's phenomenon with unilateral digital sympathectomy.
    Wasserman A; Brahn E
    Semin Arthritis Rheum; 2010 Oct; 40(2):137-46. PubMed ID: 19878974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Systemic scleroderma in children].
    Plantin P; Gavanou J; Le Fur JM; Guillet G
    Arch Fr Pediatr; 1988 Dec; 45(10):805-8. PubMed ID: 3266459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raynaud, digital ulcers and calcinosis in scleroderma.
    Nitsche A
    Reumatol Clin; 2012; 8(5):270-7. PubMed ID: 22835924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hand involvement in systemic sclerosis].
    Mouthon L
    Presse Med; 2013 Dec; 42(12):1616-26. PubMed ID: 24268960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
    Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nifedipine and Raynaud's phenomenon associated with connective tissue diseases.
    Kahan A; Weber S; Amor B; Menkes CJ; Hodara M; Degeorges M
    Int Angiol; 1985; 4(2):221-3. PubMed ID: 3831143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
    Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
    Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathogenic mechanisms in systemic sclerosis and their therapeutical consequences. Part 2: treatment].
    Zuber JP; Chizzolini C; Leimgruber A; Bart PA; Spertini F
    Rev Med Suisse; 2006 Apr; 2(62):1058, 1060-6. PubMed ID: 16711151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of nifedipine in Raynaud's phenomenon associated with systemic sclerosis.
    Thakur SK; Gopinathan VP; Jagdish TK; Bhalla IP; Shetty KJ
    J Assoc Physicians India; 1986 Jul; 34(7):536. PubMed ID: 3759897
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of biofeedback training in treatment of Raynaud's disease and phenomenon.
    Yocum DE; Hodes R; Sundstrom WR; Cleeland CS
    J Rheumatol; 1985 Feb; 12(1):90-3. PubMed ID: 3981523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions.
    Langevitz P; Buskila D; Lee P; Urowitz MB
    J Rheumatol; 1989 Nov; 16(11):1433-5. PubMed ID: 2600942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nifedipine as a therapeutic modality for Raynaud's phenomenon.
    Winston EL; Pariser KM; Miller KB; Salem DN; Creager MA
    Arthritis Rheum; 1983 Oct; 26(10):1177-80. PubMed ID: 6626276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.